ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C. The presentation highlighted t...
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
KENILWORTH, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that it has completed patient enrollment in the boceprevir HCV
SPRINT-2 study, a pivotal Phase III study in treatment-naive patients. Together with the HCV
RESPOND-2 study, a pivotal Phase...
Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
Research to be presented Sunday, November 2, 2008 at this year's liver meeting in San Francisco, California, October 31 - November 4
SAN FRANCISCO, Oct. 28 /PRNewswire/ -- Researchers from the Michael E.
DeBakey VA Medical Center, led by Jennifer Kramer, Ph.D., looked at a
population of U...
Shorter HCV treatment shows notable success
Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects. Patients HCV-RNA levels after 4 weeks o...
Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting
- Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested - - Signs of Anti-viral Activity Seen at All Dose Levels -
- Exploratory Analysis of Cytokine Profile Following Treatment Supports Proposed Immunomodulatory Mechanism ...
Transplanted fatty livers associated with worse prognosis for patients with HCV
A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis). HCV
recurrence was more frequent and earlier among those transplanted with such livers. These findings are in the January...
Obesity Makes Treatment of HCV Difficult
Research conducted by scientists at Mayo Clinic, Rochester, Minnesota has revealed that obesity was a metabolic condition, which could interfere //with the treatment for the Hepatitis C virus (HCV).
Lead researcher Dr. Michael R. Charlton and his colleagues have found that obese patients trea...
Mass. General-based research center will investigate why immune system fails to control hepatitis C
... on how some individuals successfully recover from hcv
while the infection becomes chronic in most of tho...n immunological events in the liver as the site of hcv
"Hepatitis C is a major global he...ytes in the innate and adaptive immune response to hcv
Center co-director Paul Klenerman, ...
Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
...nt duration, improve tolerability and increase cure rates. Abbott has three hcv
compounds in human trials, with additional pre-clinical compounds in develo... these new therapies, which may provide additional benefit to patients with hcv
XIENCE PRIME ...
New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...- The Standard Therapy II-2
Approved Drugs for hcv
Combination Therapy II-2
Table 2: hcv
Treatment Market in the US (2007-2010): Number
Development Stage II-3
Table 3: hcv
Treatment Market in Europe (2007): Percentage
HCV in Medical Technology
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
48-week investigational regimen yielded nearly double SVR rate compared to standard of care
Update on next-generation HCV
protease inhibitor SCH 900518 presented at EASL annual meeting
COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) toda...
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
ABBOTT PARK, Ill., and WATERTOWN, Mass., Feb. 18 /PRNewswire-FirstCall/ --
Abbott ( NYSE: ABT ) and Enanta Pharmaceuticals announced today the advancement
of their Hepatitis C (HCV) collaboration with a first-in-human study
evaluating ABT-450, an oral protease inhibitor for the treatment of ...
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Company reaffirms its innovation leadership and long-term commitment to hepatitis research
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at AASLD
SAN DIEGO, Sept. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals,
Inc. (Nasdaq: ANDS ) announced today preliminary results of a Phase I
clinical trial of ANA598 in healthy volun...
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
~ Initiates IDX184 Phase I Clinical Study and Advances HCV
Inhibitor and Non-Nucleoside Polymerase Inhibitor Clinical Candidates into IND-Enabling Preclinical Studies ~
CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX...
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
KENILWORTH, N.J., May 21 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ), a leader in hepatitis research, today announced
that it is initiating two large Phase III studies of boceprevir, its
investigational oral hepatitis C protease inhibitor, in patients
Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
CAMBRIDGE, Mass., and MILAN, Italy, April 23 /PRNewswire-FirstCall/ --
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment of
human viral and other infectious diseases, today announced preclinical data
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals,
Inc. (Nasdaq: ANDS ) presented a late-breaker oral presentation today at the
21st International Conference on Antiviral Research (ICAR) in Montreal,
Quebec, providing updated preclinical data on ANA598, a non-nucleoside
Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
--Addition of New Study Site at Leading Urban Medical Center Will Expand
the Eligible Patient Pool for the Ongoing Bavituximab HCV/HIV Co-Infection Trial--
--Dr. Sulkowski, Principal Investigator of The Johns Hopkins Study Site, Has Expertise in Studying H...
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Top Line Results of Phase II Study in Previous Nonresponders also Reported
KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today provided an update on the clinical
development program for boceprevir, its investigational oral hepatitis C
HCV in Medical Definition
Herpes zoster since 2004,
Male urethritis since 1984 and
Hepatitis A Virus ( HAV ), Hepatitis B Virus ( HBV ) and Hepatitis C Virus ( hcv
) since 2000
as well as 3 non infectious diseases :
Asthma since 2002,
Suicidal attempts since 1997 and
Hospitalizations since 19...
HCV in Medical Dictionary
...ps, driving directions and more at Yahoo! Local Find Pediatrics Continuing Medical Education (CME), Pediatrics medical journal ... Pediatric hcv
Infection May Lead to ... Pediatrics Experts & Viewpoints ... Monthly journal of the Indian Academy of Pediatrics . ... 2nd Edition of the ...
Liver function tests
...OHNSTON, M.D. ... encountered in the interpretation of common blood liver function tests . ... Liver function tests , liver disease, hcv
or chronic Hepatitis C, HBV or chronic ... Liver Function Tests . a Simple FactSheet from the AIDS Treatment Data Network ... Liver fu...
...des long term effects and recommendations for testing based on the risk for hcv
infection. From the U.S. Centers for Disease Control and Prevention. Us...rs, treatment, and self-care. Features links to news and articles about hcv
infection, its symptoms and diagnosis, treatment options, prevention, alt...
HCV in Biological News
The hepatitis healing power of blueberry leaves
...irus, opening up a new avenue for treating chronic hcv
infections, which affect 200 million people worldw...V, and though a combination drug regimen can clear hcv
infection, this treatment is only about 60% effect...cts.
Kataoka and colleagues believed that since hcv
is localized in the liver and can take 20 years or...
First human gets new antibody aimed at hepatitis C virus
...e a Phase 2 study in liver transplant patients."
attacks the liver and can eventually lead to liver....2 million Americans are chronically infected with hcv
and some 10,000 die annually of the disease. Glob...as 170 million people are estimated to suffer from hcv
infection. For the most serious cases of...
Novel antibody prevents infection by hepatitis C virus
... Mouse technology, Medarex, Inc.) with elements of hcv
and then painstakingly searched for individual hum...V1, was able to bind tightly with all genotypes of hcv
tested from infected patient samples.
MBL-HCV1 ... animals with low or no antibody dosages developed hcv
infections, but the animal with the higher dose wa...
Scripps research team identifies key molecules that inhibit viral production
...e of the critical problems in developing drugs for hcv
is that it mutates at such prodigious rates. An RN... efforts to develop therapeutic strategies against hcv
have concentrated on designing inhibitors that target several of the 10 hcv
proteins that comprise the virus, including mostly...
Leeds research points to new therapy for hepatitis C treatment
The p7 protein assists the spread of hcv
around the body and is a promising target for ne... can't be a one-size-fits-all approach to treating hcv
with p7 inhibitors in the future. We believe combi...Griffin and Prof. Harris examined the response of hcv
to a panel of compounds including the well known a...
Eltrombopag effective for hepatitis C patients with low blood-platelet counts
...170 million worldwide carry the hepatitis C virus. hcv
is transmitted primarily by blood and blood produc...or to 1990 (when screening of the blood supply for hcv
was implemented) or have used intravenous drugs. M...nt liver damage, liver cancer and death in others. hcv
infection is a common cause of cirrhosis and the m...
New class of drug offers hope to treatment-resistant AIDS patients
...vity related to the licensed patents and for drug discovery of new agents to treat patients infected with the hepatitis C virus (HCV). Co-infection by hcv
and other viruses is a problem commonly encountered by HIV-AIDS patients.
HIV relies on the activity of three key enzymes to survive and prolifera...
American Society for Microbiology honors Jason T. Blackard
...edication to his research has won him numerous fellowships and awards, including an NIH grant award in 2006 for a study of extrahepatic replication of hcv
in HIV-infected women. Blackard is also Director of his divisions GI Fellow Research Program, and he was an integral part of the University of Cincin...
Possible hepatitis C vaccine
.... Identifying regions of the virus that are able to induce broadly reactive neutralising antibodies is a significant milestone in the development of a hcv
vaccine, which will have distinct healthcare benefits for hepatitis sufferers, and could also help us design vaccines for other chronic viral diseases...
Who will recover spontaneously from hepatitis C virus infection
...ected with hepatitis C virus (HCV). The outcome of hcv
infections is either self recovery or chronic hepa...h problem worldwide.
Twenty to fifty percent of hcv
infected patients recovers spontaneously. The hepa...rt of 67 patients who spontaneously recovered from hcv
infection. In addition to these, the researchers i...
HCV in Biological Technology
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance o...
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
- Non-responder and Null Responder HCV
- Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) -
BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the innovative clinical study of protease inhibitor ITMN-191 (R7227) i...
Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
CAMBRIDGE, Mass., March 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts from the company's hepatitis C antiviral...
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44...
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
PRINCETON, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that they and their development partner, Roche, have agreed with the FDA on the final design for a phase 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
- Results of Phase 1 clinical studies support advancement to Phase 2 -
- Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors -
BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today announced that four abstracts from clinical and
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
- $15 million development milestone payment to InterMune - - Roche to lead ITMN-191 program in Phase 2 -
BRISBANE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN ) today announced that InterMune has earned a $15 million
development milestone under i...
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
CAMBRIDGE, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged
in the discovery and development of drugs for the treatment of human viral
diseases, today announced a strategic restructuring. As part of the
MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc.
(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious
diseases will present results of viral resistance studies with its anti-HCV
agent celgosivir at the 14th International Symposium on Hepatitis C Vir...
InterMune to Present at Canaccord Adams Conference
...ently in the pre-registration stage. The hepatology portfolio includes the hcv
protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation hcv
protease inhibitor research program. For additional information about Inte...
HCV in Biological Products
HCV in Biological Dictionary
...dels whereby replication of the ... posted to hcv
huh-7 ifn replicon by josealonsoneto on 2008-04-04 19:37:00 as ... posted to hcv
hur psma7 replicon sirna by danielraymond on 2...licon model were compared with the gene ... (a) hcv
...ACTIVE HUMORAL IMMUNITY . ANTIGEN DEPENDENT B CELL DEVELOPMENT ... Humoral Immunity : Review the latest approaches to developing an effective hcv
vaccine. ... Humoral Immunity . B cells play an important role in protection ... Hair and hair disease information with answers to common ques...
...tion, and more. ... Immunity , Cell Mediated Summary ... Cell - Mediated Immunity : Review the latest approaches to developing an effective hcv
vaccine. ... Humoral Immunity . Cell - Mediated Immunity . Obstacles In ... (a) T cells mediate cell - mediated immunity ... (27) Cell -...